

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APOTEX INC.,
Petitioner,

v.

CELGENE CORPORATION,
Patent Owner

Case IPR2023-00512
Patent 8,846,628

PATENT OWNER'S RESPONSE

TABLE OF CONTENTS

TABLE OF AUTHORITIES v

PATENT OWNER'S EXHIBIT LISTvi

I. INTRODUCTION 1

II. BACKGROUND3

 A. MDS and AML.....3

 B. 5-Azacytidine4

 C. The Known Challenges to Developing a Therapeutically Effective
 Formulation of 5-Azacytidine5

 D. The Therapeutic Use of 5-Azacytidine8

 1. Injectable 5-azacytidine8

 2. Oral 5-azacytidine8

III. THE '628 PATENT9

 A. The Invention of Orally Administered 5-Azacytidine9

 1. Enterically-coated formulations.....9

 2. Non-enterically coated formulations11

 B. Specification.....12

 C. Prosecution History14

 D. Challenged Claims15

 E. Onureg®15

IV. PERSON OF ORDINARY SKILL IN THE ART16

V. CLAIM CONSTRUCTION16

 A. "Non-Enteric Coated"16

 B. "Test Subject".....17

 C. Claims 14 and 1517

VI. THE ASSERTED REFERENCES18

 A. Ionescu (Ex.1004)18

 B. Atadja (Ex.1005)20

 C. Gibson (Ex.1006)21

D.	Pharmion-PR (Ex.1010).....	23
VII.	THE '628 PATENT CLAIMS ARE NOT ANTICIPATED BY IONESCU (GROUND 1).....	24
A.	Petitioner Has Failed to Show That Ionescu Discloses a Non-Enteric Coated Tablet as Required by All Challenged Claims	24
1.	Ionescu's "sugar-coated" tablets do not disclose a "non-enteric coated tablet".....	24
2.	A POSA in December 2008 would not have understood that sugar-coated tablets of 5-azacytidine would have been non-enterically coated	26
B.	Ionescu Fails to Disclose a Film Coated Tablet as Required by Claims 14 and 15	27
C.	Ionescu Does Not Inherently Anticipate the Pharmacokinetic Values Required by Claims 11, 18, 20-22, 38, 40, 42, and 43.....	27
D.	Ionescu Is Not Enabling.	29
VIII.	THE '628 PATENT CLAIMS WOULD NOT HAVE BEEN OBVIOUS IN VIEW OF IONESCU IN COMBINATION WITH ATADJA AND GIBSON AND THE KNOWLEDGE OF A POSA (GROUND 2).....	32
A.	A POSA Would Not Have Been Motivated to Pursue and Select an Oral, Non-Enteric Coated Tablet of 5-Azacytidine	32
1.	Petitioner's theory that a POSA would have selected a non-enteric coated tablet from Ionescu's disclosure is flawed for the same reasons as its anticipation challenge.....	32
2.	Petitioner has not shown that a POSA would select a non-enteric coated tablet as the "default" choice for 5-azacytidine	33
a.	Petitioner's obviousness theory cannot be reconciled with the known instability of 5-azacytidine	34
b.	There was no prior art disclosure of the use of non-enterically coated 5-azacytidine tablet	36
3.	Disclosures of "liquid formulations" would not have assuaged a POSA's concerns over 5-azacytidine's stability.....	41

4.	When read as a whole, a POSA would not credit Ionescu or Atadja as disclosing or relating to therapeutically effective oral formulations of 5-azacytidine	43
B.	Petitioner Has Failed to Establish a Reasonable Expectation of Success	46
1.	Given the well-established instability of 5-azacytidine, a POSA would not have had a reasonable expectation that a non-enteric coated tablet formulation would have been therapeutically effective.....	46
2.	Preliminary bioavailability data for unknown oral formulations does not provide a reasonable expectation that a non-enteric coated tablet of 5-azacytidine would be therapeutically effective	49
3.	The claims are not obvious to try because a non-enteric coated tablet would not have been a predictable solution for 5-azacytidine	52
C.	Ionescu, Atadja, Gibson, and Knowledge of a POSA Do Not Render Obvious Claims 6, 7, or 32.....	54
D.	Ionescu, Atadja, Gibson, and Knowledge of a POSA Do Not Render Obvious the Doses Recited in Claims 9, 24-27, and 36.....	56
E.	Ionescu, Atadja, Gibson, and Knowledge of a POSA Do Not Render Obvious The Pharmacokinetic Values Required by Claims 11, 12, 18-22 and 38-43	58
1.	Petitioner's inherency argument fails at least because the prior art does not disclose a non-enteric coated tablet	58
2.	Dr. Batchelor's modeling is faulty and does not indicate the claimed pharmacokinetic values are inherent to any formulation	59
3.	Extrapolation using Vidaza® pharmacokinetics and Pharmion-PR's bioavailability does not render obvious claims 11 and 38	62
IX.	THE '628 PATENT CLAIMS ARE NOT OBVIOUS IN VIEW OF IONESCU IN VIEW OF PHARMION-PR, ATADJA AND GIBSON AND THE KNOWLEDGE OF A POSA (GROUND 3).....	63

X. OBJECTIVE INDICIA REINFORCE THE NON-OBVIOUSNESS OF THE CHALLENGED CLAIMS64

- A. Long-felt But Unmet Need.....64
- B. Skepticism and Failure of Others66
- C. Unexpected Results68
- D. Industry Praise.....71
- E. Nexus.....73

XI. CONCLUSION.....74

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.